Similar to the 24 h long treatments, in the case of the Nrf2 inhibitor Keap-1, iron deficiency elevated its protein level, while utilization of FKN at the higher concentration significantly decreased Keap-1 expression at 48 h (Figure 5A,G). The gene discussed is KEAP1; the disease is Iron deficiency anemia.